NCT07163702

Efficacy and Safety of Xinglou Chengqi Granule for Acute Ischemic Stroke

Efficacy and Safety of Xinglou Chengqi Granule for Acute Ischemic Stroke (EXACT): a Multi-center, Randomized, Double-blinded, Dose-exploration Ⅱa Trial

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Dongzhimen Hospital, Beijing · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a Ⅱa clinical trial. The purpose of this study is to preliminarily explore the optimal dosage of Xinglou Chengqi Granules in the treatment of acute ischemic stroke and to evaluate the efficacy and safety of Xinglou Chengqi Granules for acute ischemic stroke.

Conditions

• Acute Ischemic Stroke

Interventions

Type	Name	Description
DRUG	High-dose Xinglou Chengqi granules	Patients will receive orally high-dose Xinglou Chengqi granules, combined with guidelines-based standard care.
DRUG	Low-dose Xinglou Chengqi granules and placebo	Patients will receive orally low-dose Xinglou Chengqi granules, combined with guidelines-based standard care.

Timeline

• Start date: 2025-10-01
• Primary completion: 2026-09-30
• Completion: 2026-09-30
• First posted: 2025-09-09
• Last updated: 2025-09-09

Locations

1 site across 1 country: Canada